Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-NSmut
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
MVA-NSmut is a recombinant viral vector vaccine candidate designed for the treatment and prevention of Hepatitis C virus (HCV) infection. It utilizes the Modified Vaccinia Ankara (MVA) platform to deliver a genetic sequence encoding the non-structural (NS) proteins of HCV, specifically NS3, NS4, NS5A, and NS5B. The "NSmut" designation indicates that the NS5B polymerase sequence has been genetically modified to abrogate its enzymatic activity, enhancing the safety profile of the vector. MVA-NSmut is typically employed in heterologous prime-boost immunization strategies, often administered as a boost following a priming injection with a simian adenovirus vector such as AdCh3NSmut. This regimen is intended to induce high-frequency, polyfunctional, and multi-specific T-cell responses against conserved HCV antigens to facilitate viral clearance or prevent chronic infection. The asset was originally developed by Okairos (later acquired by GSK) and has been further advanced by ReiThera.
- Other names
- Modified Vaccinia Ankara-NSmutMVA-HCV
02
Targets
NS3 (Dengue virus NS3 protein)CDKN1B (Transmembrane emp24 domain-containing protein 7)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on MVA-NSmut.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-NSmut.